BlackRock’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-883,675
| Closed | -$473K | – | 5586 |
|
|
2024
Q4 | $473K | Sell |
883,675
-975,534
| -52% | -$680K | ﹤0.01% | 4426 |
|
|
2024
Q3 | $3.27M | Sell |
1,859,209
-10,740
| -0.6% | -$15K | ﹤0.01% | 3849 |
|
|
2024
Q2 | $2.19M | Sell |
1,869,949
-2,850,612
| -60% | -$7.13M | ﹤0.01% | 3942 |
|
|
2024
Q1 | $42.7M | Buy |
4,720,561
+121,283
| +3% | +$1.18M | ﹤0.01% | 2534 |
|
|
2023
Q4 | $50M | Buy |
4,599,278
+453,635
| +11% | +$3.4M | ﹤0.01% | 2472 |
|
|
2023
Q3 | $33.4M | Buy |
4,145,643
+247,873
| +6% | +$2.06M | ﹤0.01% | 2639 |
|
|
2023
Q2 | $42.3M | Buy |
3,897,770
+2,769,357
| +245% | +$23.7M | ﹤0.01% | 2589 |
|
|
2023
Q1 | $7.79M | Buy |
1,128,413
+50,463
| +5% | +$316K | ﹤0.01% | 3449 |
|
|
2022
Q4 | $4.29M | Buy |
1,077,950
+118,752
| +12% | +$584K | ﹤0.01% | 3795 |
|
|
2022
Q3 | $6.38M | Buy |
959,198
+17,887
| +2% | +$110K | ﹤0.01% | 3643 |
|
|
2022
Q2 | $4.56M | Sell |
941,311
-1,684,717
| -64% | -$10.2M | ﹤0.01% | 3862 |
|
|
2022
Q1 | $24.6M | Sell |
2,626,028
-390,861
| -13% | -$3.88M | ﹤0.01% | 3040 |
|
|
2021
Q4 | $35.8M | Buy |
3,016,889
+19,686
| +0.7% | +$227K | ﹤0.01% | 2898 |
|
|
2021
Q3 | $34.1M | Sell |
2,997,203
-17,825
| -0.6% | -$245K | ﹤0.01% | 2912 |
|
|
2021
Q2 | $54.1M | Buy |
3,015,028
+288,390
| +11% | +$4.64M | ﹤0.01% | 2646 |
|
|
2021
Q1 | $42.2M | Buy |
2,726,638
+646,547
| +31% | +$9.35M | ﹤0.01% | 2728 |
|
|
2020
Q4 | $25.4M | Buy |
2,080,091
+327,588
| +19% | +$4.57M | ﹤0.01% | 2890 |
|
|
2020
Q3 | $22.5M | Buy |
1,752,503
+285,539
| +19% | +$2.46M | ﹤0.01% | 2789 |
|
|
2020
Q2 | $14.9M | Buy |
1,466,964
+170,007
| +13% | +$1.56M | ﹤0.01% | 2959 |
|
|
2020
Q1 | $10.5M | Buy |
1,296,957
+384,219
| +42% | +$3.33M | ﹤0.01% | 2963 |
|
|
2019
Q4 | $7.89M | Buy |
912,738
+32,788
| +4% | +$184K | ﹤0.01% | 3359 |
|
|
2019
Q3 | $5.42M | Buy |
879,950
+23,015
| +3% | +$186K | ﹤0.01% | 3463 |
|
|
2019
Q2 | $14.2M | Buy |
856,935
+57,453
| +7% | +$998K | ﹤0.01% | 3039 |
|
|
2019
Q1 | $13.4M | Buy |
799,482
+189,957
| +31% | +$2.74M | ﹤0.01% | 2963 |
|
|
2018
Q4 | $7M | Sell |
609,525
-118,076
| -16% | -$2.39M | ﹤0.01% | 3265 |
|
|
2018
Q3 | $29.1M | Buy |
727,601
+64,948
| +10% | +$1.85M | ﹤0.01% | 2675 |
|
|
2018
Q2 | $18.7M | Buy |
662,653
+503,693
| +317% | +$11.2M | ﹤0.01% | 2902 |
|
|
2018
Q1 | $2.43M | Sell |
158,960
-9,161
| -5% | -$218K | ﹤0.01% | 3629 |
|
|
2017
Q4 | $5.49M | Buy |
168,121
+122,781
| +271% | +$3.31M | ﹤0.01% | 3408 |
|
|
2017
Q3 | $1.06M | Buy |
45,340
+3,718
| +9% | +$41.7K | ﹤0.01% | 3897 |
|
|
2017
Q2 | $228K | Sell |
41,622
-17,106
| -29% | -$92.5K | ﹤0.01% | 4223 |
|
|
2017
Q1 | $416K | Buy |
+58,728
| New | +$316K | ﹤0.01% | 4015 |
|
BlackRock's MRNS Position: Q1 2025 in Review
BlackRock sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 883,675 shares — an estimated $473K sold.
BlackRock first reported a position in MRNS in Q1 2017 and held it in 32 quarters. The position peaked at $54.1M in Q2 2021. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- BlackRock reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- BlackRock sold 883,675 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $473K.
- BlackRock first reported a position in Marinus Pharmaceuticals, Inc in Q1 2017 and held it in 32 quarters.
- BlackRock's Marinus Pharmaceuticals, Inc position peaked at $54.1M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.